2021

主页/标签: 2021

Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism

NEW YORK, Aug. 16, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP), (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Diabetes, Obesity, and Metabolism, has published an original article titled "Efficacy and safety of 28-day [...]

2021-08-16T08:25:00+00:00分类:新闻通稿|标签:|

Oravax to Present Keynote Talk on Oral COVID-19 Vaccine at the Arena International Vaccines Virtual Conference 2021

Keynote Talk: Development of the World's First Triple Antigen Oral SARS Cov-2 Vaccine NEW YORK, Aug. 5, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that its [...]

2021-08-05T06:40:00+00:00分类:新闻通稿|标签:|

Oramed Pharmaceuticals Appoints Chief Commercial Officer

NEW YORK, July 29, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Michael Rabinowitz to the newly created position of Chief Commercial Officer effective [...]

2021-07-29T08:25:00+00:00分类:新闻通稿|标签:|

Oramed Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial

- Oravax's virus-like particle (VLP) vaccine being tested against COVID-19 variants including Delta - Oravax signs licensing deal for VLP injectable vaccine technology with Premas Biotech for commercialization in India NEW YORK, July 21, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a [...]

2021-07-21T08:25:00+00:00分类:新闻通稿|标签:|